findmyKOL

Christian Ruff, MD

Enriched profile

Director, General Cardiology, Cardiovascular Division, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School · Brigham and Women's Hospital

ORCIDNPI
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyCardiovascular DiseaseFocusCoronary Artery Disease / ACS
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Christian Ruff is Director, General Cardiology, Cardiovascular Division, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School at Brigham and Women's Hospital. OpenAlex indexes 331 publications with 30,842 citations (h-index 58); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Cardiovascular Disease profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Christian Ruff, MD, is Director, General Cardiology, Cardiovascular Division, Brigham and Women's Hospital. The public record shows 331 publications with 30,842 citations (h-index 58), centered on Coronary Artery Disease / ACS. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 10 companies.

  • Most recent indexed publication: 2026 · Nature medicine
  • Top research focus: Coronary Artery Disease / ACS
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Coronary Artery Disease / ACS1 trialMyocardial Infarction1 trialInfarction1 trial

Research focus

OpenAlex concept fingerprint
Coronary Artery Disease / ACS

Drugs & molecules

across trials, industry payments and publications
Savaysageneric · EdoxabanClinical trialsIndustry payments4Publications2Lokelmageneric · Sodium zirconium cyclosilicateClinical trialsIndustry payments4PublicationsEliquisgeneric · ApixabanClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Janssen Research & Development, LLCClinical trialsIndustry payments16Novartis Pharmaceuticals CorporationClinical trialsIndustry payments8Regeneron Pharmaceuticals, Inc.Clinical trialsIndustry payments7

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
331publications

Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.

30,842citations

Total citations across indexed works.

58h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    71.9%
    Statin18.4%
    Atorvastatin Calcium64%Rosuvastatin Calcium36%
    Part D20 patients
    Beta blocker14.5%
    Metoprolol Succinate100%
    Part D24 patients
  • Blood & clotting

    19.1%
    Factor Xa inhibitor14.5%
    Eliquis100%
    Part D15 patients
    P2Y12 inhibitor4.7%
    Clopidogrel100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    9%
    Potassium supplement3.5%
    Potassium Chloride100%
    Part D<11 patients
    SGLT2 inhibitor3.3%
    Jardiance100%
    Part D<11 patients
Where care is delivered (Part B)91.8% facility · 8.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/christian-ruff-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.